{"id":881680,"date":"2025-09-03T16:19:18","date_gmt":"2025-09-03T20:19:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\/"},"modified":"2025-09-03T16:19:18","modified_gmt":"2025-09-03T20:19:18","slug":"sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\/","title":{"rendered":"SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">MIAMI, Sept.  03, 2025  (GLOBE NEWSWIRE) &#8212; SAB Biotherapeutics, Inc. (Nasdaq:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VZJDtsJX50R6jrswloYDpyC6Acbh2RbsWh5WpsCVzlx7tUQUnmaNQbREdLhuztwkOQi52Cw4opPcXAHnShnCT3rappBeYRcF9LcxRNXFNhl7gbE3JGBxN_paYNDzcaQE\" rel=\"nofollow\" target=\"_blank\">SABS<\/a>), (\u201cSAB BIO\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a multi-specific human anti-thymocyte immunoglobulin (hIgG) for delaying the onset and progression of autoimmune type 1 diabetes (T1D), today announced\u00a0that it will present at the 61<sup>st<\/sup> Annual Meeting of the European Association for the Study of Diabetes (EASD) being held September 15 \u2013 19, 2025 at the VIECON &#8211; Vienna Congress &amp; Convention Center in Vienna, Austria. The Company will have four oral presentations, as well as an INNODIA-hosted symposium at EASD.<\/p>\n<p>Information on all presentations is below:<\/p>\n<p>\n        <strong><br \/>\n          <u>INNODIA EASD Symposium | Life-Changing T1D Therapies Symposium<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Working to Change the Lives of People Impacted <\/strong><br \/>\n        <strong>\u200b<\/strong><br \/>\n        <strong>by Type 1 Diabetes Through Unique<\/strong><br \/>\n        <strong>\u00a0Disease-Modifying Therapy<\/strong><br \/>\n        <br \/>\n        <strong>Presenter: <\/strong>Alexandra Kropotova, MD, MBA, EVP and Chief Medical Officer <br \/><strong>Presentation Date &amp; Time: <\/strong>Monday, September 15, 2025 | 16:40 \u2013 20:00 CEST <br \/><strong>Location:<\/strong> Lima Hall<\/p>\n<p>\n        <strong><br \/>\n          <u>EASD Presentations:<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Immunomodulation Without Sustained Lymphodepletion: SAB-142, a Fully Human <\/strong><br \/>\n        <strong>Anti-Thymocyte Globulin<\/strong><br \/>\n        <br \/>\n        <strong>Session: <\/strong>Behind the Screens: Adventures in T1D Clinical Trials\u00a0| Presentation 19<br \/><strong>Presenter: <\/strong>Alexandra Kropotova, MD, MBA, EVP and Chief Medical Officer <br \/><strong>Presentation Date &amp; Time: <\/strong> Tuesday, September 16, 2025 | 10:00 \u2013 11:30 CEST<br \/><strong>Location: <\/strong> Mumbai Hall<\/p>\n<p>\n        <strong>Mechanism of Action of a Fully Human Anti-Thymocyte Globulin, SAB-142, for the Treatment <\/strong><br \/>\n        <strong>of Type 1 Diabetes<\/strong><br \/>\n        <br \/>\n        <strong>Session: <\/strong> OP 28 \u201cGuardians of the Islet Galaxy: Protect and Replace\u201d | Presentation 163<br \/><strong>Presenter:<\/strong> Christoph Bausch, PhD, EVP and Chief Operating Officer <br \/><strong>Presentation Date &amp; Time:<\/strong> Thursday, September 18, 2025 | 10:45 \u2013 12:15 CEST <br \/><strong>Location:<\/strong> Sofia Hall<\/p>\n<p>\n        <strong>Novel Pharmacokinetic Assay for Measuring SAB-142, a Fully Human Anti-Thymocyte Globulin<\/strong><br \/>\n        <br \/>\n        <strong>Session:<\/strong> Clinical Tales from the T1D Trenches | Short Oral Discussion &#8211; Event F | Presentation 391<br \/><strong>Presenter:<\/strong>\u00a0\u00a0 Eric Sandhurst, PhD, Director of Program Management<br \/><strong>Presentation Date &amp; Time: <\/strong>Thursday, September 18, 2025 | 14:00 \u2013 15:00 CEST <br \/><strong>Location: <\/strong>Station 03, Hall C<\/p>\n<p>\n        <strong>Specimen Quality for Multicenter Clinical Trials: Comparing Novel Blood Preservation Methods to Cryopreserved PBMC<\/strong><br \/>\n        <br \/>\n        <strong>Session: <\/strong>Clinical Tales from the T1D Trenches | Short Oral Discussion &#8211; Event F | Presentation 392<br \/><strong>Presenter:<\/strong>\u00a0\u00a0 Eric Sandhurst, PhD, Director of Program Management<br \/><strong>Presentation Date &amp; Time:<\/strong>\u00a0\u00a0 Thursday, September 18, 2025 | 14:00 \u2013 15:00 CEST <br \/><strong>Location: <\/strong>Station 03, Hall C<\/p>\n<p>\n        <strong>About EASD Annual Meeting <\/strong>\n      <\/p>\n<p>The EASD Annual Meeting is the largest diabetes conference in the world, attracting thousands of delegates. The program showcases the latest results from basic and clinical research.<\/p>\n<p>For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1HjMnCB5ypu7-iJVHnuFeyyS3tCLyJ7_nD74L_Fg77Da8AfkZGDhHHLcZ-sHUxcL1neNHK-_u6qW1JitN0o0c50r0XS_Tkokft3VmR8bfMX8nanFqDsbxAMfEPQWLmvQ56whX_ZQvLDVs5gGzkx5fRKE3zcaQar4OTvHq94g1yM=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.easd.org\/annual-meeting\/easd-2025\/<\/a>.<\/p>\n<p>\n        <strong>About INNODIA<\/strong>\n      <\/p>\n<p>INNODIA\u00a0is an international non-profit organization that stemmed from\u00a0a European-based public-private\u00a0partnership co-funded by the European Commission\u2019s Innovative Medicines Initiative (IMI-JU Joint Undertaking), The Hemsley Charitable Trust, Breakthrough T1D, and EFPIA partners.\u00a0Thanks to this\u00a0unique private-public interaction,\u00a0INNODIA has become the largest\u00a0European Network dedicated to prevent and cure type 1 diabetes and today it is a legal entity that represents the interface between those who want to develop new therapies and those who have the tools and experience to do so.<\/p>\n<p>For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1HjMnCB5ypu7-iJVHnuFe0iPyEips1Q1Qbs2AkXHffiREsFjLbd4KFPtVPrh9tFmWLpzDllISwyu-8iOm6-Y76sMN_bdRqHRF3jUSnBYB4M=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.innodia.eu\/<\/a>.<\/p>\n<p>\n        <strong>About SAB BIO<\/strong>\n      <\/p>\n<p>SAB BIO is a clinical-stage biopharmaceutical company focused on developing human, multi-specific, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company\u2019s lead asset, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine\u2122, the only transgenic animal with a human artificial chromosome, SAB BIO\u2019s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, human IgGs that can address a wide range of serious unmet needs in human diseases without the need for convalescent plasma or human donors.<\/p>\n<p>\n        <strong>CONTACTS<\/strong>\n      <\/p>\n<p>\n        <u>Investor Relations<\/u>:<br \/>Kevin Gardner<br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zaPTYALC91nhCypFT4g3080XbmEqKj7J9IfbMc5cTOCy-R1P-ncZibnIn07Lwp8SROzxJcbI5ttOW-upUsbztDVw-pivZA7VAX3BdSnGE3juZeRMGROp85TsFZ3BCnaF3CfNhkticnzWLLChJKgrTJwNxJtIFTvSyk8Kz0mMlARsdU6365ufyHUVKj9cH2-1XbOWdUUsxOMKD39gseCtXIVu8NXhHlPpk6Qgs0Ux9M8loelDqZtj0u-jp9FmUMTBbtoX8_rWjyiXf6MfwfotW2c76jTr4zMsSV9Xz4hllESXulKW_RsZQpMPTsDgy1hW\" rel=\"nofollow\" target=\"_blank\">kgardner@lifesciadvisors.com<\/a><\/p>\n<p>\n        <u>Media Inquiries<\/u>:<br \/>SAB BIO<br \/>Sheila Carlson<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kbZYWcKouBfeNElLhOVrk7_VH8Xuc2vB06m57jbkZgpJaGQ2C6fH0dbSEKsWlPaXzpx9lUdZ8KlWvozTdUsur8bY1Uac_-HRv7YEw2Z850o=\" rel=\"nofollow\" target=\"_blank\">scarlson@sab.bio<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjg5MiM3MTI5MTQzIzIyMjE3NDE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MGQ5NDY2NGQtMjQzNi00NTJhLWE1MTktZWIwZjIwYzRkNTAyLTEyMzMyOTQtMjAyNS0wOS0wMy1lbg==\/tiny\/SAB-Biotherapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) &#8212; SAB Biotherapeutics, Inc. (Nasdaq:\u00a0SABS), (\u201cSAB BIO\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a multi-specific human anti-thymocyte immunoglobulin (hIgG) for delaying the onset and progression of autoimmune type 1 diabetes (T1D), today announced\u00a0that it will present at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) being held September 15 \u2013 19, 2025 at the VIECON &#8211; Vienna Congress &amp; Convention Center in Vienna, Austria. The Company will have four oral presentations, as well as an INNODIA-hosted symposium at EASD. Information on all presentations is below: INNODIA EASD Symposium | Life-Changing T1D Therapies Symposium Working to Change the Lives of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-881680","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) &#8212; SAB Biotherapeutics, Inc. (Nasdaq:\u00a0SABS), (\u201cSAB BIO\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a multi-specific human anti-thymocyte immunoglobulin (hIgG) for delaying the onset and progression of autoimmune type 1 diabetes (T1D), today announced\u00a0that it will present at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) being held September 15 \u2013 19, 2025 at the VIECON &#8211; Vienna Congress &amp; Convention Center in Vienna, Austria. The Company will have four oral presentations, as well as an INNODIA-hosted symposium at EASD. Information on all presentations is below: INNODIA EASD Symposium | Life-Changing T1D Therapies Symposium Working to Change the Lives of &hellip; Continue reading &quot;SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-03T20:19:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjg5MiM3MTI5MTQzIzIyMjE3NDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes\",\"datePublished\":\"2025-09-03T20:19:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\\\/\"},\"wordCount\":632,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjg5MiM3MTI5MTQzIzIyMjE3NDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\\\/\",\"name\":\"SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjg5MiM3MTI5MTQzIzIyMjE3NDE=\",\"datePublished\":\"2025-09-03T20:19:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjg5MiM3MTI5MTQzIzIyMjE3NDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjg5MiM3MTI5MTQzIzIyMjE3NDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\/","og_locale":"en_US","og_type":"article","og_title":"SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes - Market Newsdesk","og_description":"MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) &#8212; SAB Biotherapeutics, Inc. (Nasdaq:\u00a0SABS), (\u201cSAB BIO\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a multi-specific human anti-thymocyte immunoglobulin (hIgG) for delaying the onset and progression of autoimmune type 1 diabetes (T1D), today announced\u00a0that it will present at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) being held September 15 \u2013 19, 2025 at the VIECON &#8211; Vienna Congress &amp; Convention Center in Vienna, Austria. The Company will have four oral presentations, as well as an INNODIA-hosted symposium at EASD. Information on all presentations is below: INNODIA EASD Symposium | Life-Changing T1D Therapies Symposium Working to Change the Lives of &hellip; Continue reading \"SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-03T20:19:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjg5MiM3MTI5MTQzIzIyMjE3NDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes","datePublished":"2025-09-03T20:19:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\/"},"wordCount":632,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjg5MiM3MTI5MTQzIzIyMjE3NDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\/","name":"SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjg5MiM3MTI5MTQzIzIyMjE3NDE=","datePublished":"2025-09-03T20:19:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjg5MiM3MTI5MTQzIzIyMjE3NDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjg5MiM3MTI5MTQzIzIyMjE3NDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-deliver-five-presentations-related-to-sab-142-at-the-2025-annual-meeting-of-the-european-association-for-the-study-of-diabetes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/881680","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=881680"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/881680\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=881680"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=881680"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=881680"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}